Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...

Chronic hepatitis B virus (HBV) infection continues to pose a major global health threat. The virus evades immune responses and antiviral therapies due to the persistence of covalently closed circular ...

Hepatitis B virus (HBV) is the leading cause of cirrhosis, hepatocellular carcinoma, and liver-related death globally.1,2 The highest prevalence is found in low-income and middle-income countries ...

Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma.

and HBV DNA loss to below the limits of detection in 9% to 10% of participants with chronic HBV infection. That is below the 30% rate reported at an interim stage of the study at the International ...

The US joins Moldova, Hong Kong, and New Zealand as countries to greenlight the company's Phase I trial of PBGENE-HBV.

Institute of Materials, École Polytechnique Fédérale de Lausanne (EPFL), Station 12, Lausanne CH-1015, Switzerland ...